The subscription period in Prolight Diagnostics AB (publ) rights issue of units starts today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Prolight Diagnostics AB (publ) publishes prospectus in connection with rights issue of units
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 27 November 2023
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) (the “Company”) took place on 27 November 2023 in Lund. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below. Resolution regarding the change of the articles of associationThe EGM resolved to […]
Prolight Diagnostics achieves ISO 13485 accreditation
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, today announces that their subsidiary Psyros Diagnostics has gained accreditation to the industry standard ISO 13485, which sets out the requirements for a quality management system (QMS) specific to the medical devices industry. “The accreditation shows that our quality processes meet global quality requirements which is […]
Prolight Diagnostics shows proof of performance in whole blood
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample. “This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single […]
Notice of extraordinary general meeting in Prolight Diagnostics AB (publ)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Monday 27 November 2023 at 11 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc. Shareholders who wish to participate in the extraordinary general meeting must: […]
Prolight Diagnostics forms Clinical Advisory Board
Prolight Diagnostics (“Prolight”) is pleased to announce the formation of its Clinical Advisory Board with the appointment of six distinguished, internationally recognized experts in the field of cardiology, emergency medicine and clinical pathology. The Clinical Advisory Board will be instrumental in the further product development and clinical studies of Prolight’s unique digital, single molecule counting, […]
Prolight Diagnostics publishes investor letter for October 2023
Prolight Diagnostics publishes an investor letter for October 2023. In the investor letter, an interview is given with Karl Bullen, COO at Prolight Diagnostics. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, a first summary of the Congress Annual Scientific Meeting + Clinical Lab Expo in Anaheim, USA is given. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics, together with […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company’s new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics […]
